Page last updated: 2024-11-05

troglitazone and Vasculitis

troglitazone has been researched along with Vasculitis in 2 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Verrier, E1
Wang, L1
Wadham, C1
Albanese, N1
Hahn, C1
Gamble, JR1
Chatterjee, VK1
Vadas, MA1
Xia, P1
Pasceri, V1
Wu, HD1
Willerson, JT1
Yeh, ET1

Other Studies

2 other studies available for troglitazone and Vasculitis

ArticleYear
PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase.
    Circulation research, 2004, Jun-11, Volume: 94, Issue:11

    Topics: Animals; Aorta; Cattle; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Chromans; Diabetic

2004
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.
    Circulation, 2000, Jan-25, Volume: 101, Issue:3

    Topics: Animals; Arteriosclerosis; Cell Movement; Cells, Cultured; Chromans; Endothelium, Vascular; Humans;

2000